No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 24
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Olema Pharmaceuticals, Inc. (OLMA) stock was $7.99 as of Oct 6, 2026, 1:50 PM EDT, down 3.21% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -25.6% · 3-year avg -13.4%/yr · 5-year avg -21.5%/yr
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc.
Biotechnology · San Francisco, CA
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.60
Revenue Est.
$1.25M
Last Quarter Results
EPS
$-0.61
vs Estimate
$-0.56
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OLMA | $697.47M | $7.99 | -3.21% | -25.57% | -21.50% | N/A | N/A |
| 2AVR | $699.10M | $7.19 | -4.77% | +74.71% | N/A | N/A | vs OLMA |
| 3AVTX | $695.44M | $13.23 | -9.38% | +8.91% | -70.04% | -48.70% | vs OLMA |
| 4COLL | $710.98M | $21.92 | +0.23% | -36.67% | +2.15% | +1.39% | vs OLMA |
| 5FTH | $713.41M | $27.67 | +2.12% | +182.36% | -31.75% | N/A | vs OLMA |
| 6SLDB | $681.27M | $6.92 | -1.98% | +19.56% | -27.50% | N/A | vs OLMA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 10 analysts
Average Price Target
$36.50
+357.1% upside
Low
$16.00
Current
$7.99
High
$59.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.69 | $-0.64 | $-0.53 | 7 |
| Quarter ending Dec 2026 | $-0.73 | $-0.66 | $-0.54 | 7 |
| Quarter ending Mar 2027 | $-0.64 | $-0.64 | $-0.64 | 2 |
| Quarter ending Jun 2027 | $-0.65 | $-0.65 | $-0.65 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.41 | $-2.39 | $-2.33 | 6 |
| FY 2027 | $-3.03 | $-2.66 | $-2.44 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.25M | $1.25M | $1.25M | 5 |
| Quarter ending Dec 2026 | $1.56M | $1.56M | $1.56M | 4 |
| Quarter ending Mar 2027 | $4.10M | $4.10M | $4.10M | 4 |
| Quarter ending Jun 2027 | $5.94M | $5.94M | $5.94M | 4 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.22M | $2.25M | $3.20M | 6 |
| FY 2027 | $4.39M | $8.19M | $14.36M | 7 |
